Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 75 EUR
  • 25 mg - 300 EUR
  • 100 mg - 900 EUR

GDC-0449

GDC-0449 is a small, orally available inhibitor of the Hedgehog (Hh) pathway, which is involved in tumorigenesis. This provides a strong rationale for its use in the treatment of various cancers. The compound suppresses Hh signaling by binding to and interfering with smoothened (with an IC50 of 3 nM), a membrane protein that provides positive signals to the Hh signaling pathway. Vismodegib is currently undergoing phase II clinical trials for the treatment of advanced BCC, metastatic colorectal cancer, ovarian cancer, MB and other solid tumors. Because of its low toxicity and specificity for the Hh pathway, this drug has potential advantages over conventional chemotherapeutic agents and could potentially be useful in combination treatments.

catalogue number: G033
synonyms: Vismodegib, Erivedge
CAS: 879085-55-9
MW: 421.3 g/mol

References
Curr Opin Investig Drugs. 2010 Jun;11(6):707-18. PMID: 20496266